NO313963B1 - 4-okso-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid- derivater, medikamenter og farmasöytiske preparater - Google Patents

4-okso-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid- derivater, medikamenter og farmasöytiske preparater Download PDF

Info

Publication number: NO313963B1
Authority: NO; Norway
Prior art keywords: mmol; methyl; dihydro; indole; phenyl
Prior art date: 1997-07-30

Application number

NO20000462A

Other languages

English (en)

Norwegian (no)

Other versions

NO20000462D0 (no

NO20000462L (no

Inventor

Yannick Evanno

Laurent Dubois

Mireille Sevrin

Frank Marguet

Jacques Froissant

Regine Bartsch

Catherine Gille

Original Assignee

Sanofi Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-30

Filing date

2000-01-28

Publication date

2003-01-06

2000-01-28 Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo

2000-01-28 Publication of NO20000462D0 publication Critical patent/NO20000462D0/no

2000-03-29 Publication of NO20000462L publication Critical patent/NO20000462L/no

2003-01-06 Publication of NO313963B1 publication Critical patent/NO313963B1/no

Links

229940079593 drug Drugs 0.000 title claims description 5
239000003814 drug Substances 0.000 title claims description 5
239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
QYGVTWDMEAZITC-UHFFFAOYSA-N 2-(4-oxo-3,5-dihydropyridazino[4,5-b]indol-1-yl)acetamide Chemical class N1C2=CC=CC=C2C2=C1C(=O)NN=C2CC(=O)N QYGVTWDMEAZITC-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 73
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
-1 phenylmethoxy group Chemical group 0.000 claims description 16
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
239000001257 hydrogen Substances 0.000 claims description 9
229910052739 hydrogen Inorganic materials 0.000 claims description 9
125000000217 alkyl group Chemical group 0.000 claims description 8
229910052757 nitrogen Inorganic materials 0.000 claims description 7
125000002393 azetidinyl group Chemical group 0.000 claims description 5
125000005843 halogen group Chemical group 0.000 claims description 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
125000002757 morpholinyl group Chemical group 0.000 claims description 4
125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
125000003386 piperidinyl group Chemical group 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 105
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 60
239000000203 mixture Substances 0.000 description 54
239000000243 solution Substances 0.000 description 54
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 40
239000007787 solid Substances 0.000 description 36
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
238000010992 reflux Methods 0.000 description 30
238000001914 filtration Methods 0.000 description 28
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
238000002844 melting Methods 0.000 description 27
230000008018 melting Effects 0.000 description 27
239000002904 solvent Substances 0.000 description 25
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
239000000047 product Substances 0.000 description 24
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 22
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
239000012074 organic phase Substances 0.000 description 20
239000002244 precipitate Substances 0.000 description 20
239000011541 reaction mixture Substances 0.000 description 20
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
229960000583 acetic acid Drugs 0.000 description 15
238000002360 preparation method Methods 0.000 description 15
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
238000012360 testing method Methods 0.000 description 13
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
239000000741 silica gel Substances 0.000 description 12
229910002027 silica gel Inorganic materials 0.000 description 12
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
238000004587 chromatography analysis Methods 0.000 description 11
238000000034 method Methods 0.000 description 11
230000000694 effects Effects 0.000 description 10
229910052938 sodium sulfate Inorganic materials 0.000 description 10
235000011152 sodium sulphate Nutrition 0.000 description 10
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
239000000725 suspension Substances 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical group NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 8
229940067157 phenylhydrazine Drugs 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
238000010908 decantation Methods 0.000 description 7
238000003756 stirring Methods 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
241000700159 Rattus Species 0.000 description 6
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
238000011835 investigation Methods 0.000 description 6
229910052943 magnesium sulfate Inorganic materials 0.000 description 6
235000019341 magnesium sulphate Nutrition 0.000 description 6
HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 6
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 5
210000001638 cerebellum Anatomy 0.000 description 5
OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 5
229960004381 flumazenil Drugs 0.000 description 5
239000002198 insoluble material Substances 0.000 description 5
210000000278 spinal cord Anatomy 0.000 description 5
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
230000000949 anxiolytic effect Effects 0.000 description 4
KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 4
239000011521 glass Substances 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
150000002825 nitriles Chemical class 0.000 description 4
239000012279 sodium borohydride Substances 0.000 description 4
229910000033 sodium borohydride Inorganic materials 0.000 description 4
239000012312 sodium hydride Substances 0.000 description 4
229910000104 sodium hydride Inorganic materials 0.000 description 4
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
NGTQLLKQKAUYMI-UHFFFAOYSA-N 2-(8-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound O=C1C=2N(C)C3=CC=C(Cl)C=C3C=2C(CC(O)=O)=NN1C1=CC=CC=C1 NGTQLLKQKAUYMI-UHFFFAOYSA-N 0.000 description 3
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
150000001299 aldehydes Chemical class 0.000 description 3
230000001773 anti-convulsant effect Effects 0.000 description 3
239000001961 anticonvulsive agent Substances 0.000 description 3
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 3
230000000147 hypnotic effect Effects 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000010907 mechanical stirring Methods 0.000 description 3
239000012071 phase Substances 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 3
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 3
CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 3
238000011282 treatment Methods 0.000 description 3
SRUOLCVDPWORFN-UHFFFAOYSA-N 1-(bromomethyl)-5-ethyl-8-fluoro-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(CC)C3=CC=C(F)C=C3C=2C(CBr)=NN1C1=CC=CC=C1 SRUOLCVDPWORFN-UHFFFAOYSA-N 0.000 description 2
FYIYGLQUOXPNJH-UHFFFAOYSA-N 1-(bromomethyl)-8-chloro-5-methyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(C)C3=CC=C(Cl)C=C3C=2C(CBr)=NN1C1=CC=CC=C1 FYIYGLQUOXPNJH-UHFFFAOYSA-N 0.000 description 2
AIHUBJRDRLESCF-UHFFFAOYSA-N 1-(bromomethyl)-8-fluoro-5-(methoxymethyl)-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(COC)C3=CC=C(F)C=C3C=2C(CBr)=NN1C1=CC=CC=C1 AIHUBJRDRLESCF-UHFFFAOYSA-N 0.000 description 2
ZNXISFSKCMPYIL-UHFFFAOYSA-N 2-(5,8-dimethyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetonitrile Chemical compound C12=CC(C)=CC=C2N(C)C(C2=O)=C1C(CC#N)=NN2C1=CC=CC=C1 ZNXISFSKCMPYIL-UHFFFAOYSA-N 0.000 description 2
DZZZGQHDTKHZAL-UHFFFAOYSA-N 2-(5-ethyl-8-fluoro-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)-n,n-dimethylacetamide Chemical compound O=C1C=2N(CC)C3=CC=C(F)C=C3C=2C(CC(=O)N(C)C)=NN1C1=CC=CC=C1 DZZZGQHDTKHZAL-UHFFFAOYSA-N 0.000 description 2
SHDYVPKEQTWDQE-UHFFFAOYSA-N 2-(5-ethyl-8-fluoro-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound O=C1C=2N(CC)C3=CC=C(F)C=C3C=2C(CC(O)=O)=NN1C1=CC=CC=C1 SHDYVPKEQTWDQE-UHFFFAOYSA-N 0.000 description 2
CCRKQAZAOJLVKW-UHFFFAOYSA-N 2-(5-ethyl-8-fluoro-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetonitrile Chemical compound O=C1C=2N(CC)C3=CC=C(F)C=C3C=2C(CC#N)=NN1C1=CC=CC=C1 CCRKQAZAOJLVKW-UHFFFAOYSA-N 0.000 description 2
NYMOTNIJLGLDHN-UHFFFAOYSA-N 2-(5-methyl-4-oxo-3-phenyl-8-phenylmethoxypyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound C1=C2C=3C(CC(O)=O)=NN(C=4C=CC=CC=4)C(=O)C=3N(C)C2=CC=C1OCC1=CC=CC=C1 NYMOTNIJLGLDHN-UHFFFAOYSA-N 0.000 description 2
AIZUWNQXNBXSFP-UHFFFAOYSA-N 2-(5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound O=C1C=2N(C)C3=CC=CC=C3C=2C(CC(O)=O)=NN1C1=CC=CC=C1 AIZUWNQXNBXSFP-UHFFFAOYSA-N 0.000 description 2
XKNQLOVDKJOJCA-UHFFFAOYSA-N 2-(7-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetonitrile Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(CC#N)=NN1C1=CC=CC=C1 XKNQLOVDKJOJCA-UHFFFAOYSA-N 0.000 description 2
AFGDZGKETASTNL-UHFFFAOYSA-N 2-(8-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetonitrile Chemical compound O=C1C=2N(C)C3=CC=C(Cl)C=C3C=2C(CC#N)=NN1C1=CC=CC=C1 AFGDZGKETASTNL-UHFFFAOYSA-N 0.000 description 2
YCBJPRYHHFSCRH-UHFFFAOYSA-N 2-(8-fluoro-4-oxo-3-phenyl-5H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide Chemical compound CN(C)C(=O)Cc1nn(-c2ccccc2)c(=O)c2[nH]c3ccc(F)cc3c12 YCBJPRYHHFSCRH-UHFFFAOYSA-N 0.000 description 2
WNTMLIQMCCQQLR-UHFFFAOYSA-N 2-(8-fluoro-4-oxo-3-phenyl-5H-pyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound OC(=O)Cc1nn(-c2ccccc2)c(=O)c2[nH]c3ccc(F)cc3c12 WNTMLIQMCCQQLR-UHFFFAOYSA-N 0.000 description 2
XKIRNYLZSARPBF-UHFFFAOYSA-N 2-(9-bromo-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound O=C1C=2N(C)C3=CC=CC(Br)=C3C=2C(CC(O)=O)=NN1C1=CC=CC=C1 XKIRNYLZSARPBF-UHFFFAOYSA-N 0.000 description 2
HXKGNDPKXMSGMT-UHFFFAOYSA-N 2-(9-bromo-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetonitrile Chemical compound O=C1C=2N(C)C3=CC=CC(Br)=C3C=2C(CC#N)=NN1C1=CC=CC=C1 HXKGNDPKXMSGMT-UHFFFAOYSA-N 0.000 description 2
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
WKNOKWQTCZFTLM-UHFFFAOYSA-N 2-[8-fluoro-5-(methoxymethyl)-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl]acetonitrile Chemical compound O=C1C=2N(COC)C3=CC=C(F)C=C3C=2C(CC#N)=NN1C1=CC=CC=C1 WKNOKWQTCZFTLM-UHFFFAOYSA-N 0.000 description 2
USLAQWFFBBGFJX-UHFFFAOYSA-N 5-ethyl-8-fluoro-1-(hydroxymethyl)-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(CC)C3=CC=C(F)C=C3C=2C(CO)=NN1C1=CC=CC=C1 USLAQWFFBBGFJX-UHFFFAOYSA-N 0.000 description 2
URUIZLQLWKNJGV-UHFFFAOYSA-N 7-chloro-1-(hydroxymethyl)-5-methyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(CO)=NN1C1=CC=CC=C1 URUIZLQLWKNJGV-UHFFFAOYSA-N 0.000 description 2
KUSUYSHAZYRLMM-UHFFFAOYSA-N 7-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indole-1-carbaldehyde Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(C=O)=NN1C1=CC=CC=C1 KUSUYSHAZYRLMM-UHFFFAOYSA-N 0.000 description 2
NOMQDNNEHXUVRB-UHFFFAOYSA-N 8-fluoro-1-(hydroxymethyl)-5-(methoxymethyl)-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(COC)C3=CC=C(F)C=C3C=2C(CO)=NN1C1=CC=CC=C1 NOMQDNNEHXUVRB-UHFFFAOYSA-N 0.000 description 2
BRMAFUSPPQZPBT-UHFFFAOYSA-N 9-bromo-1,5-dimethyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(C)C3=CC=CC(Br)=C3C=2C(C)=NN1C1=CC=CC=C1 BRMAFUSPPQZPBT-UHFFFAOYSA-N 0.000 description 2
XQZYRONQCQPFCC-UHFFFAOYSA-N 9-bromo-1-(bromomethyl)-5-methyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(C)C3=CC=CC(Br)=C3C=2C(CBr)=NN1C1=CC=CC=C1 XQZYRONQCQPFCC-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010053398 Clonic convulsion Diseases 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
239000012359 Methanesulfonyl chloride Substances 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000005903 acid hydrolysis reaction Methods 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
229960003965 antiepileptics Drugs 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000027455 binding Effects 0.000 description 2
239000012455 biphasic mixture Substances 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
230000036461 convulsion Effects 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
229960003529 diazepam Drugs 0.000 description 2
150000005690 diesters Chemical class 0.000 description 2
238000001035 drying Methods 0.000 description 2
UGCPBPJTNIDYCS-UHFFFAOYSA-N ethyl 1-ethyl-5-fluoroindole-2-carboxylate Chemical compound FC1=CC=C2N(CC)C(C(=O)OCC)=CC2=C1 UGCPBPJTNIDYCS-UHFFFAOYSA-N 0.000 description 2
OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 2
VIKOQTQMWBKMNA-UHFFFAOYSA-N ethyl 5-fluoro-1h-indole-2-carboxylate Chemical compound FC1=CC=C2NC(C(=O)OCC)=CC2=C1 VIKOQTQMWBKMNA-UHFFFAOYSA-N 0.000 description 2
QMVJTCIUKISOGR-UHFFFAOYSA-N ethyl 6-chloro-1-methylindole-2-carboxylate Chemical compound C1=C(Cl)C=C2N(C)C(C(=O)OCC)=CC2=C1 QMVJTCIUKISOGR-UHFFFAOYSA-N 0.000 description 2
YAIVDGZDNCFDNH-UHFFFAOYSA-N ethyl 6-chloro-3-(2-ethoxy-2-oxoacetyl)-1-methylindole-2-carboxylate Chemical compound ClC1=CC=C2C(C(=O)C(=O)OCC)=C(C(=O)OCC)N(C)C2=C1 YAIVDGZDNCFDNH-UHFFFAOYSA-N 0.000 description 2
JJCGYLAKDUJYLK-UHFFFAOYSA-N ethyl 7-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indole-1-carboxylate Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(C(=O)OCC)=NN1C1=CC=CC=C1 JJCGYLAKDUJYLK-UHFFFAOYSA-N 0.000 description 2
UOBUAOPQJRUMIS-UHFFFAOYSA-N ethyl 8-fluoro-4-oxo-3-phenyl-5H-pyridazino[4,5-b]indole-1-carboxylate Chemical compound FC1=CC=2C3=C(NC2C=C1)C(N(N=C3C(=O)OCC)C3=CC=CC=C3)=O UOBUAOPQJRUMIS-UHFFFAOYSA-N 0.000 description 2
YPIJONONGVJKOI-UHFFFAOYSA-N ethyl 8-fluoro-5-(methoxymethyl)-4-oxo-3-phenylpyridazino[4,5-b]indole-1-carboxylate Chemical compound O=C1C=2N(COC)C3=CC=C(F)C=C3C=2C(C(=O)OCC)=NN1C1=CC=CC=C1 YPIJONONGVJKOI-UHFFFAOYSA-N 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000003193 general anesthetic agent Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
150000002431 hydrogen Chemical group 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
229960003350 isoniazid Drugs 0.000 description 2
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
239000012528 membrane Substances 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
CINPLCMEILSUTJ-UHFFFAOYSA-N methyl 2-azido-3-(2-bromophenyl)prop-2-enoate Chemical compound COC(=O)C(N=[N+]=[N-])=CC1=CC=CC=C1Br CINPLCMEILSUTJ-UHFFFAOYSA-N 0.000 description 2
NIIZOBJLUXKGRH-UHFFFAOYSA-N methyl 3-acetyl-4-bromo-1-methylindole-2-carboxylate Chemical compound C1=CC=C2N(C)C(C(=O)OC)=C(C(C)=O)C2=C1Br NIIZOBJLUXKGRH-UHFFFAOYSA-N 0.000 description 2
OIMNSVYNDCDFHZ-UHFFFAOYSA-N methyl 4-bromo-1-methylindole-2-carboxylate Chemical compound C1=CC=C2N(C)C(C(=O)OC)=CC2=C1Br OIMNSVYNDCDFHZ-UHFFFAOYSA-N 0.000 description 2
FFELLMINXHHZFW-UHFFFAOYSA-N methyl 5-ethyl-8-fluoro-4-oxo-3-phenylpyridazino[4,5-b]indole-1-carboxylate Chemical compound O=C1C=2N(CC)C3=CC=C(F)C=C3C=2C(C(=O)OC)=NN1C1=CC=CC=C1 FFELLMINXHHZFW-UHFFFAOYSA-N 0.000 description 2
IZITWQUNZSRMSQ-UHFFFAOYSA-N methyl 8-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indole-1-carboxylate Chemical compound O=C1C=2N(C)C3=CC=C(Cl)C=C3C=2C(C(=O)OC)=NN1C1=CC=CC=C1 IZITWQUNZSRMSQ-UHFFFAOYSA-N 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
MCLGZNGDLWVKKA-UHFFFAOYSA-N n,n-dimethyl-2-(5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetamide Chemical compound O=C1C=2N(C)C3=CC=CC=C3C=2C(CC(=O)N(C)C)=NN1C1=CC=CC=C1 MCLGZNGDLWVKKA-UHFFFAOYSA-N 0.000 description 2
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
230000008569 process Effects 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
238000000746 purification Methods 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000035939 shock Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
150000003511 tertiary amides Chemical class 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 2
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
125000006526 (C1-C2) alkyl group Chemical group 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
MTOCNSSVLMHZSL-UHFFFAOYSA-N 1-(chloromethyl)-5,8-dimethyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound C12=CC(C)=CC=C2N(C)C(C2=O)=C1C(CCl)=NN2C1=CC=CC=C1 MTOCNSSVLMHZSL-UHFFFAOYSA-N 0.000 description 1
BPWDOIOAEBSMEI-UHFFFAOYSA-N 1-(hydroxymethyl)-5,8-dimethyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound C12=CC(C)=CC=C2N(C)C(C2=O)=C1C(CO)=NN2C1=CC=CC=C1 BPWDOIOAEBSMEI-UHFFFAOYSA-N 0.000 description 1
UEFGLENGHNNEBY-UHFFFAOYSA-N 1-methoxyethanol hydrate Chemical compound O.COC(C)O UEFGLENGHNNEBY-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
YZLXFDAHJQYGHP-UHFFFAOYSA-N 2-(5,8-dimethyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound C12=CC(C)=CC=C2N(C)C(C2=O)=C1C(CC(O)=O)=NN2C1=CC=CC=C1 YZLXFDAHJQYGHP-UHFFFAOYSA-N 0.000 description 1
KEJBHBACUIULHT-UHFFFAOYSA-N 2-(5-methyl-4-oxo-3-phenyl-8-phenylmethoxypyridazino[4,5-b]indol-1-yl)acetonitrile Chemical compound C1=C2C=3C(CC#N)=NN(C=4C=CC=CC=4)C(=O)C=3N(C)C2=CC=C1OCC1=CC=CC=C1 KEJBHBACUIULHT-UHFFFAOYSA-N 0.000 description 1
IVAXNAPQNKKHNX-UHFFFAOYSA-N 2-(7-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)-n,n-diethylacetamide Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(CC(=O)N(CC)CC)=NN1C1=CC=CC=C1 IVAXNAPQNKKHNX-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
NDOPHXWIAZIXPR-UHFFFAOYSA-N 2-bromobenzaldehyde Chemical compound BrC1=CC=CC=C1C=O NDOPHXWIAZIXPR-UHFFFAOYSA-N 0.000 description 1
HJIIDZAZBHFECW-UHFFFAOYSA-N 5-methyl-1-(2-oxo-2-pyrrolidin-1-ylethyl)-3-phenyl-8-phenylmethoxypyridazino[4,5-b]indol-4-one Chemical compound C1=C2C=3C(CC(=O)N4CCCC4)=NN(C=4C=CC=CC=4)C(=O)C=3N(C)C2=CC=C1OCC1=CC=CC=C1 HJIIDZAZBHFECW-UHFFFAOYSA-N 0.000 description 1
JOJFFFHUQBCTQM-UHFFFAOYSA-N 5-methyl-1-(2-oxo-2-pyrrolidin-1-ylethyl)-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound N=1N(C=2C=CC=CC=2)C(=O)C=2N(C)C3=CC=CC=C3C=2C=1CC(=O)N1CCCC1 JOJFFFHUQBCTQM-UHFFFAOYSA-N 0.000 description 1
CAFYGGQVXCLTCG-UHFFFAOYSA-N 8-chloro-1-(hydroxymethyl)-5-methyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(C)C3=CC=C(Cl)C=C3C=2C(CO)=NN1C1=CC=CC=C1 CAFYGGQVXCLTCG-UHFFFAOYSA-N 0.000 description 1
CAEBDSZCRVKXBJ-UHFFFAOYSA-N 8-chloro-5-methyl-1-(2-oxo-2-pyrrolidin-1-ylethyl)-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound N=1N(C=2C=CC=CC=2)C(=O)C=2N(C)C3=CC=C(Cl)C=C3C=2C=1CC(=O)N1CCCC1 CAEBDSZCRVKXBJ-UHFFFAOYSA-N 0.000 description 1
DPMQMIJSGBQYIF-UHFFFAOYSA-N 9-bromo-5-methyl-1-(2-oxo-2-pyrrolidin-1-ylethyl)-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound N=1N(C=2C=CC=CC=2)C(=O)C=2N(C)C3=CC=CC(Br)=C3C=2C=1CC(=O)N1CCCC1 DPMQMIJSGBQYIF-UHFFFAOYSA-N 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
108010062745 Chloride Channels Proteins 0.000 description 1
102000011045 Chloride Channels Human genes 0.000 description 1
XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
208000027776 Extrapyramidal disease Diseases 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
206010062575 Muscle contracture Diseases 0.000 description 1
241000208125 Nicotiana Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
108010064114 carbon dioxide receptor Proteins 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000007806 chemical reaction intermediate Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000012320 chlorinating reagent Substances 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
208000006111 contracture Diseases 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000007350 electrophilic reaction Methods 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
DFGMZWFTGORNFX-UHFFFAOYSA-N ethyl 1-ethyl-5-fluoro-3-(2-methoxy-2-oxoacetyl)indole-2-carboxylate Chemical compound FC1=CC=C2N(CC)C(C(=O)OCC)=C(C(=O)C(=O)OC)C2=C1 DFGMZWFTGORNFX-UHFFFAOYSA-N 0.000 description 1
CVNBHZZQKTYQBE-UHFFFAOYSA-N ethyl 3-(2-ethoxy-2-oxoacetyl)-5-fluoro-1h-indole-2-carboxylate Chemical compound C1=C(F)C=C2C(C(=O)C(=O)OCC)=C(C(=O)OCC)NC2=C1 CVNBHZZQKTYQBE-UHFFFAOYSA-N 0.000 description 1
GECRCAVZSPCTDM-UHFFFAOYSA-N ethyl 5-chloro-1-methylindole-2-carboxylate Chemical compound ClC1=CC=C2N(C)C(C(=O)OCC)=CC2=C1 GECRCAVZSPCTDM-UHFFFAOYSA-N 0.000 description 1
HNQSPSRSXQCGGV-UHFFFAOYSA-N ethyl 5-chloro-3-(2-methoxy-2-oxoacetyl)-1-methylindole-2-carboxylate Chemical compound ClC1=CC=C2N(C)C(C(=O)OCC)=C(C(=O)C(=O)OC)C2=C1 HNQSPSRSXQCGGV-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229940005494 general anesthetics Drugs 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
230000026781 habituation Effects 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
WQJFIWXYPKYBTO-UHFFFAOYSA-N indole-1-acetic acid Chemical compound C1=CC=C2N(CC(=O)O)C=CC2=C1 WQJFIWXYPKYBTO-UHFFFAOYSA-N 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
PAALEOQOHSOLGW-UHFFFAOYSA-N methyl 2-(7-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetate Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(CC(=O)OC)=NN1C1=CC=CC=C1 PAALEOQOHSOLGW-UHFFFAOYSA-N 0.000 description 1
RXYCUKSOYJWGPE-UHFFFAOYSA-N methyl 2-azidoacetate Chemical compound COC(=O)CN=[N+]=[N-] RXYCUKSOYJWGPE-UHFFFAOYSA-N 0.000 description 1
DTPOJMDJBBGYFK-UHFFFAOYSA-N methyl 4-bromo-1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OC)=CC2=C1Br DTPOJMDJBBGYFK-UHFFFAOYSA-N 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
239000003880 polar aprotic solvent Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
239000011698 potassium fluoride Substances 0.000 description 1
235000003270 potassium fluoride Nutrition 0.000 description 1
238000009101 premedication Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003334 secondary amides Chemical class 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
210000004894 snout Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000007428 synaptic transmission, GABAergic Effects 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Addiction (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Indole Compounds (AREA)

NO20000462A 1997-07-30 2000-01-28 4-okso-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid- derivater, medikamenter og farmasöytiske preparater NO313963B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9709692A FR2766823B1 (fr)	1997-07-30	1997-07-30	Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
PCT/FR1998/001667 WO1999006406A1 (fr)	1997-07-30	1998-07-28	DERIVES DE 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b] INDOLE-1-ACETAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Publications (3)

Publication Number	Publication Date
NO20000462D0 NO20000462D0 (no)	2000-01-28
NO20000462L NO20000462L (no)	2000-03-29
NO313963B1 true NO313963B1 (no)	2003-01-06

Family

ID=9509801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20000462A NO313963B1 (no)	1997-07-30	2000-01-28	4-okso-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid- derivater, medikamenter og farmasöytiske preparater

Country Status (33)

Country	Link
US (1)	US6262045B1 (ja)
EP (1)	EP1000063B1 (ja)
JP (1)	JP4322421B2 (ja)
KR (1)	KR100497782B1 (ja)
CN (1)	CN1134440C (ja)
AR (1)	AR013264A1 (ja)
AT (1)	ATE226584T1 (ja)
AU (1)	AU736600B2 (ja)
BG (1)	BG64283B1 (ja)
BR (1)	BR9811582B1 (ja)
CA (1)	CA2298522C (ja)
CO (1)	CO5210883A1 (ja)
CZ (1)	CZ290011B6 (ja)
DE (1)	DE69808921T2 (ja)
DK (1)	DK1000063T3 (ja)
EE (1)	EE04317B1 (ja)
ES (1)	ES2186212T3 (ja)
FR (1)	FR2766823B1 (ja)
HK (1)	HK1028027A1 (ja)
HU (1)	HU229430B1 (ja)
IL (1)	IL133633A (ja)
NO (1)	NO313963B1 (ja)
NZ (1)	NZ502361A (ja)
PL (1)	PL194245B1 (ja)
PT (1)	PT1000063E (ja)
RU (1)	RU2197490C2 (ja)
SI (1)	SI1000063T1 (ja)
SK (1)	SK283075B6 (ja)
TR (1)	TR200000278T2 (ja)
TW (1)	TW506971B (ja)
UA (1)	UA57088C2 (ja)
WO (1)	WO1999006406A1 (ja)
ZA (1)	ZA986786B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2788776B1 (fr) *	1999-01-26	2001-02-23	Synthelabo	Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) *	1999-01-26	2004-03-05	Synthelabo	Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
GB0000564D0 (en) *	2000-01-11	2000-03-01	Merck Sharp & Dohme	Therapeutic agents
FR2811897A1 (fr) *	2000-07-24	2002-01-25	Sanofi Synthelabo	UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
FR2811990A1 (fr) *	2000-07-24	2002-01-25	Sanofi Synthelabo	DERIVES DE 1-(4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1 -CARBONYL)PIPERAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2833953B1 (fr) *	2001-12-21	2004-12-03	Sanofi Synthelabo	DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-b]INDOLE-1-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2838124B1 (fr)	2002-04-03	2004-05-28	Sanofi Synthelabo	Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
JP5483874B2 (ja) *	2005-05-05	2014-05-07	サノフィ−アベンティス・ユー・エス・エルエルシー	安定なナノ粒子処方物
ES2414434T3 (es) *	2005-08-29	2013-07-19	Sanofi-Aventis U.S. Llc	Dispersiones sólidas amorfas de 7-cloro-N,N,5-trimetil-4-oxo-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida
UA91716C2 (ru) *	2005-08-29	2010-08-25	САНОФИ-АВЕНТИС Ю.Эс. ЭлЭлСи	НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА ПРОИЗВОДНОГО ПИРИДАЗИНО[4,5-b]ИНДОЛА
JP2009508966A (ja) *	2005-09-23	2009-03-05	シェーリングコーポレイション	治療薬としての縮合四環性ｍＧｌｕＲ１アンタゴニスト
CN1946120B (zh) *	2006-10-20	2010-05-12	华为技术有限公司	实现话单关联的方法及***
KR20110052640A (ko) *	2008-08-18	2011-05-18	사노피-아벤티스 유.에스. 엘엘씨	7-클로로-Ｎ,Ｎ,5-트리메틸-4-옥소-3-페닐-3,5-디하이드로-4Ｈ-피리다지노[4,5-ｂ]인돌-1-아세트아미드의 다형체의 제조방법
EP2181717A1 (en)	2008-10-28	2010-05-05	Sanofi-Aventis	Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-B]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4985560A (en) *	1990-01-12	1991-01-15	American Home Products Corporation	Pyridazino(4,5-b)indolizines
GB9411955D0 (en) *	1994-06-15	1994-08-03	Merck Sharp & Dohme	Therapeutic agents
US5756501A (en) *	1995-12-13	1998-05-26	American Home Products Corporation	Saturated and unsaturated pyridazino 4,5-B! indolizines useful as antidementia agents
FR2754262B1 (fr) *	1996-10-08	1998-10-30	Synthelabo	Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique

1997
- 1997-07-30 FR FR9709692A patent/FR2766823B1/fr not_active Expired - Fee Related
1998
- 1998-07-28 IL IL13363398A patent/IL133633A/en active IP Right Grant
- 1998-07-28 ES ES98941468T patent/ES2186212T3/es not_active Expired - Lifetime
- 1998-07-28 EP EP98941468A patent/EP1000063B1/fr not_active Expired - Lifetime
- 1998-07-28 AU AU89832/98A patent/AU736600B2/en not_active Ceased
- 1998-07-28 DK DK98941468T patent/DK1000063T3/da active
- 1998-07-28 UA UA99127213A patent/UA57088C2/uk unknown
- 1998-07-28 US US09/463,634 patent/US6262045B1/en not_active Expired - Lifetime
- 1998-07-28 SI SI9830309T patent/SI1000063T1/xx unknown
- 1998-07-28 TR TR2000/00278T patent/TR200000278T2/xx unknown
- 1998-07-28 JP JP2000505164A patent/JP4322421B2/ja not_active Expired - Fee Related
- 1998-07-28 SK SK129-2000A patent/SK283075B6/sk not_active IP Right Cessation
- 1998-07-28 WO PCT/FR1998/001667 patent/WO1999006406A1/fr active IP Right Grant
- 1998-07-28 HU HU0002650A patent/HU229430B1/hu not_active IP Right Cessation
- 1998-07-28 CN CNB988076071A patent/CN1134440C/zh not_active Expired - Fee Related
- 1998-07-28 KR KR10-2000-7000935A patent/KR100497782B1/ko not_active IP Right Cessation
- 1998-07-28 PT PT98941468T patent/PT1000063E/pt unknown
- 1998-07-28 DE DE69808921T patent/DE69808921T2/de not_active Expired - Lifetime
- 1998-07-28 PL PL98338445A patent/PL194245B1/pl not_active IP Right Cessation
- 1998-07-28 BR BRPI9811582-0A patent/BR9811582B1/pt not_active IP Right Cessation
- 1998-07-28 CZ CZ2000320A patent/CZ290011B6/cs not_active IP Right Cessation
- 1998-07-28 NZ NZ502361A patent/NZ502361A/en not_active IP Right Cessation
- 1998-07-28 EE EEP200000056A patent/EE04317B1/xx not_active IP Right Cessation
- 1998-07-28 RU RU2000102672/04A patent/RU2197490C2/ru not_active IP Right Cessation
- 1998-07-28 AT AT98941468T patent/ATE226584T1/de active
- 1998-07-28 CA CA002298522A patent/CA2298522C/en not_active Expired - Fee Related
- 1998-07-29 TW TW087112458A patent/TW506971B/zh not_active IP Right Cessation
- 1998-07-29 ZA ZA986786A patent/ZA986786B/xx unknown
- 1998-07-29 CO CO98043191A patent/CO5210883A1/es active IP Right Grant
- 1998-07-29 AR ARP980103713A patent/AR013264A1/es active IP Right Grant
2000
- 2000-01-20 BG BG104096A patent/BG64283B1/bg unknown
- 2000-01-28 NO NO20000462A patent/NO313963B1/no not_active IP Right Cessation
- 2000-11-16 HK HK00107288A patent/HK1028027A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
BR9811582A (pt)	2000-09-26
PL194245B1 (pl)	2007-05-31
US6262045B1 (en)	2001-07-17
CO5210883A1 (es)	2002-10-30
JP2001512122A (ja)	2001-08-21
EP1000063B1 (fr)	2002-10-23
CN1134440C (zh)	2004-01-14
DE69808921D1 (de)	2002-11-28
CA2298522A1 (en)	1999-02-11
JP4322421B2 (ja)	2009-09-02
IL133633A (en)	2004-02-08
BG64283B1 (bg)	2004-08-31
HK1028027A1 (en)	2001-02-02
HU229430B1 (en)	2013-12-30
NO20000462D0 (no)	2000-01-28
HUP0002650A3 (en)	2002-09-30
CA2298522C (en)	2008-07-15
TR200000278T2 (tr)	2000-08-21
KR20010022356A (ko)	2001-03-15
KR100497782B1 (ko)	2005-06-27
TW506971B (en)	2002-10-21
BR9811582B1 (pt)	2010-10-19
EE04317B1 (et)	2004-06-15
ZA986786B (en)	1999-02-02
ES2186212T3 (es)	2003-05-01
SI1000063T1 (en)	2003-04-30
IL133633A0 (en)	2001-04-30
AR013264A1 (es)	2000-12-13
NZ502361A (en)	2001-06-29
PL338445A1 (en)	2000-11-06
EE200000056A (et)	2000-10-16
CN1265108A (zh)	2000-08-30
NO20000462L (no)	2000-03-29
AU8983298A (en)	1999-02-22
CZ2000320A3 (cs)	2000-05-17
UA57088C2 (uk)	2003-06-16
FR2766823A1 (fr)	1999-02-05
ATE226584T1 (de)	2002-11-15
SK1292000A3 (en)	2000-08-14
RU2197490C2 (ru)	2003-01-27
DK1000063T3 (da)	2003-02-24
DE69808921T2 (de)	2003-07-03
WO1999006406A1 (fr)	1999-02-11
AU736600B2 (en)	2001-08-02
SK283075B6 (sk)	2003-02-04
CZ290011B6 (cs)	2002-05-15
EP1000063A1 (fr)	2000-05-17
HUP0002650A2 (hu)	2001-01-29
BG104096A (en)	2000-08-31
PT1000063E (pt)	2003-03-31
FR2766823B1 (fr)	1999-10-08

Legal Events

Date	Code	Title	Description
2015-02-23	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
FI88504B (fi)	1993-02-15	Foerfarande foer framstaellning av terapeutiskt anvaendbara 4-benzyl-1-(2h)-ftalazinonderivat
NO313963B1 (no)	2003-01-06	4-okso-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid- derivater, medikamenter og farmasöytiske preparater
CN104995191A (zh)	2015-10-21	三环喹啉和喹喔啉衍生物
DK164704B (da)	1992-08-03	3,6-disubstituerede triazolo-oe3,4-aaa-ftalazinderivater, fremgangsmaade til fremstilling deraf, udgangsforbindelse til anvendelse i fremgangsmaaden samt anvendelse af og farmaceutisk praeparat indeholdende forbindelserne
US6075021A (en)	2000-06-13	1H-pyrido[3,4-b]indole-4-carboxamide derivatives, preparation and application thereof in therapeutics
PT85936B (pt)	1990-07-31	Processo para a preparacao de 4,5-di-hidro- e 4,5,6,7-tetra-hidro-pirazolo {-1-5-a}-pirimidinas
US5512590A (en)	1996-04-30	5,6-dihydro-4h-imidazo 2',1':2,3!imidazo- 4,5,1-ij!quinoline and 4,5-dihydroimidazo- 1,2-a!pyrolo 1,2,3-cd!benzimidazole derivatives, their preparation and application in therapeutics
IE922342A1 (en)	1993-01-27	Imidazo[2,1-b]benzothiazole-3-acetamide derivatives, their¹preparation and their use in therapeutics
DK2121602T3 (en)	2015-04-07	4- (Heterocyclyl) alkyl-N- (arylsulfonyl) -INDOLFORBINDELSER and their use as 5-HT 6 ligands
SK4694A3 (en)	1995-02-08	9h-imidazo (1,2,-a) benzimidazole-3-acetamide derivatives method of their preparation and pharmaceutical compounds containing these derivatives
US3557095A (en)	1971-01-19	Pyrazolodiazepinone compounds
MXPA00001009A (en)	2001-05-07	4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b
US4515949A (en)	1985-05-07	[2-(1H-indol-1-yl)ethyl]-2-piperazine and pyrido[1,2-a]indol-9-one as intermediates for pyrazino(2,3-3,4)pyrido(1,2-a) indoles which are useful for treating hypertension in mammals
EP0115920A2 (en)	1984-08-15	Pyrazino(2',3'-3,4)pyrido(1,2-a) indole derivatives
US4816461A (en)	1989-03-28	7,8,9,10-tetrahydrothieno[3,2-e]pyrido[4,3-b] indole, a process for their preparation and medicaments containing them
CZ291893A3 (en)	1994-07-13	DERIVATIVES OF 2-THIENYLIMIDAZO(2,1-b)BENZOTHIAZOLE-3-ACETIC ACID, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS IN WHICH THEY ARE COMPRISED
NO811671L (no)	1981-11-17	Benzazepinderivater.